News
- 2024/11/01
- Presentation of a global phase II clinical study of a novel ROS1 inhibitor, taletrectinib, in patients with advanced ROS1-positive Non-Small Cell Lung Cancer.
- 2024/10/10
- Annual update has been made to our Sustainability site.
- 2024/05/08
- Received ‘AA’ for the first time in MSCI ESG Ratings
- 2023/12/15
- NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
- 2023/10/19
- Updated information of sustainability
- 2023/10/18
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
- 2023/09/25
-
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.
- 2022/11/16
-
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody
- 2021/06/30
-
New Late-Breaking Data at The American Diabetes Association Show GlycoMark May Be an Effective Test for COVID-19 Severity
- 2020/07/06
-
Pict Leap Co., Ltd has developed “ Liquid Crystal Display Which Can Be Photographed By Infrared Camera ”
- 2020/02/07
-
Pict Leap Co., Ltd has developed "32-inch off-grid outdoor display system
- 2019/11/22
- Nippon Kayaku launches PortrazzaⓇ Injection, a human anti EGFR Monoclonal Antibody
- 2019/10/01
- MicroChem Corp (MCC) has changed its name to Kayaku Advanced Materials, Inc.(KAM)
- 2019/08/21
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Dosage & Administration of Breast Cancer with HER2 Overexpression
- 2019/06/18
- Transfer of Marketing Authorization for humanized anti EGFR Monoclonal Antibody PORTRAZZAⓇ, in JAPAN
- 2019/05/30
- Management Changes (Appointments & Transfers)
- 2019/04/22
- NIPPON KAYAKU and Eli Lilly Enter into Licensing Agreement of Necitumumab, a humanized anti EGFR Monoclonal Antibody, in JAPAN